Everything below concerns AOD9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The addition of bicarbonate to the intravenous fluids may alleviate acidosis (high acid level of the blood) and make the urine more alkaline to prevent cast formation in the kidneys; evidence suggesting that bicarbonate has benefits above saline alone is limited, and it can worsen hypocalcemia by enhancing calcium and phosphate deposition in the tissues. If urine alkalinization is used, the pH of the urine is kept at 6.5 or above. Furosemide, a loop diuretic, is often used to ensure sufficient urine production, but evidence that this prevents kidney failure is lacking.
The southern African territory of Rhodesia, officially Southern Rhodesia, was a unique case in the British Empire and Commonwealth: although a colony in name, it was internally self-governing and constitutionally not unlike a dominion. This situation dated back to 1923, when it was granted responsible government within the empire as a self-governing colony, following three decades of administration and development by the British South Africa Company. Britain had intended Southern Rhodesia's integration into the Union of South Africa as a new province, but this having been rejected by registered voters in the 1922 government referendum, the territory was moulded into a prospective dominion instead. It was empowered to run its own affairs in almost all respects, including defence. Whitehall's powers over Southern Rhodesia under the 1923 constitution were, on paper, considerable; the British Crown was theoretically able to cancel any passed bill within a year, or alter the constitution however it wished. These reserved powers were intended to protect the indigenous black Africans from discriminatory legislation and to safeguard British commercial interests in the colony, but as Claire Palley comments in her constitutional history of the country, it would have been extremely difficult for Whitehall to enforce such actions, and attempting to do so would have probably caused a crisis. In the event, they were never exercised. A generally co-operative relationship developed between Whitehall and the colonial government and civil service in Salisbury, and dispute was rare.
=== Linkage isomerization === Linkage isomerism occurs with ligands with more than one donor atom, known as ambidentate ligands. For example, nitrite can coordinate through O or N. One pair of nitrite linkage isomers have structures (NH3)5CoNO2+2 (nitro isomer) and (NH3)5CoONO2+ (nitrito isomer).
=== Competitive === In competitive inhibition the substrate and inhibitor cannot bind to the enzyme at the same time. This usually results from the inhibitor having an affinity for the active site of an enzyme where the substrate also binds; the substrate and inhibitor compete for access to the enzyme's active site. This type of inhibition can be overcome by sufficiently high concentrations of substrate (Vmax remains constant), i.e., by out-competing the inhibitor. However, the apparent Km will increase as it takes a higher concentration of the substrate to reach the Km point, or half the Vmax. Competitive inhibitors are often similar in structure to the real substrate (see for example the "methotrexate versus folate" figure in the "Drugs" section).
== Tolerance and overdoses == Fatal opioid overdose typically occurs due to bradypnea, hypoxemia, and decreased cardiac output (hypotension occurs due to vasodilation, and bradycardia further contributes to decreased cardiac output). A potentiation effect occurs when opioids are combined with ethanol, benzodiazepines, barbiturates, or other central depressants which can result in rapid loss of consciousness and an increased risk of fatal overdose. Substantial tolerance to respiratory depression develops quickly, and tolerant individuals can withstand larger doses. However, tolerance to respiratory depression is quickly lost during withdrawal and may be completely reversed within a week. Many overdoses occur in people who return to their previous dose after having lost their tolerance following cessation of opioids. This puts addicts who receive medical treatment for opioid addiction at great risk of overdose when they are released, as they may be particularly vulnerable to relapse. Less commonly, massive overdoses have been known to cause circulatory collapse from vasodilation and bradycardia. Opioid overdoses can be rapidly reversed through the use of opioid antagonists, naloxone being the most widely used example. Opioid antagonists work by binding competitively to μ-opioid receptors and displacing opioid agonists. Additional doses of naloxone may be necessary and supportive care should be given to prevent hypoxic brain injury by monitoring vital signs.
Sources: en.wikipedia.org
The Salmonella Mutagenesis test (Ames test) uses multiple strains of Salmonella typhimurium that are auxotrophic to histidine to test whether a given chemical can cause mutations by observing its auxotrophic property in response to an added chemical compound. The mutation a chemical substance or compound causes is measured by applying it to the bacteria on a plate containing histidine then moving the bacteria to a new plate without sufficient histidine for continual growth. If the substance does not mutate the genome of the bacteria from auxotrophic to histidine back to prototrophic to histidine, then the bacteria would not show growth on the new plate. So by comparing the ratio of the bacteria on the new plate to the old plate and the same ratio for the control group, it is possible to quantify how mutagenic a substance is, or rather, how likely it is to cause mutations in DNA. A chemical is considered positive for Ames test if it causes mutations increasing the observed reversion rate and negative if presents similar to the control group. There is a normal, but small, number of revertant colonies expected when an auxotrophic bacteria is plated on a media without the metabolite it needs because it could mutate back to prototrophy. The chances of this are low and therefore cause very small colonies to be formed. If a mutagenic substance is added, however, the number of revertants would be visibly higher than without the mutagenic substance.
== Further reading == Krönig, A. (1856), "Grundzüge einer Theorie der Gase", Annalen der Physik, 001 (10): 315–22, Bibcode:1856AnP...175..315K, doi:10.1002/andp.18561751008. Facsimile at the Bibliothèque nationale de France (pp. 315–22). Clausius, R. (1857), "Ueber die Art der Bewegung, welche wir Wärme nennen", Annalen der Physik und Chemie, 176 (3): 353–79, Bibcode:1857AnP...176..353C, doi:10.1002/andp.18571760302. Facsimile at the Bibliothèque nationale de France (pp. 353–79). Joseph Louis Gay-Lussac – Liste de ses communications, archived from the original on October 23, 2005 . (in French)
==== Orientation ==== Most often, a burial will be oriented to a specific direction for religious purposes, as are the case for persons of the Abrahamic faiths. Standard Jewish burials are made supine east-west, with the head at the western end of the grave, in order to face Jerusalem. In other cases, the body may be buried on a north-south axis, or, simply facing towards the exit of the cemetery or burial grounds. This is done in order to facilitate the return to Israel foretold of all those who are resurrected at the end of time following the coming of the Messiah. Historically, Christian burials followed similar principles, where the body was placed east-west, to mirror the layout of Christian churches, which were themselves oriented as such for much the same reason; to view the coming of Christ on Judgment day (Eschaton). In many Christian traditions, ordained clergy are traditionally buried in the opposite orientation, and their coffins carried likewise, so that at the General Resurrection they may rise facing, and ready to minister to, their people. In an Islamic funeral, the grave should be aligned perpendicular to the Qibla (the direction to the Kaaba in Mecca) with the face turned to the right along the Qibla.
The first large, diverse lineage of short-tailed avialans to evolve were the Enantiornithes, or "opposite birds", so named because the construction of their shoulder bones was in reverse to that of modern birds. Enantiornithes occupied a wide array of ecological niches, from sand-probing shorebirds and fish-eaters to tree-dwelling forms and seed-eaters. While they were the dominant group of avialans during the Cretaceous period, Enantiornithes became extinct along with many other dinosaur groups at the end of the Mesozoic era. Many species of the second major avialan lineage to diversify, the Euornithes (meaning "true birds", because they include the ancestors of modern birds), were semi-aquatic and specialised in eating fish and other small aquatic organisms. Unlike the Enantiornithes, which dominated land-based and arboreal habitats, most early euornithians lacked perching adaptations and likely included shorebird-like species, waders, and swimming and diving species. The latter included the superficially gull-like Ichthyornis and the Hesperornithiformes, which became so well adapted to hunting fish in marine environments that they lost the ability to fly and became primarily aquatic. The early euornithians also saw the development of many traits associated with modern birds, like strongly keeled breastbones, toothless, beaked portions of their jaws (though most non-avian euornithians retained teeth in other parts of the jaws).
== Expression == In insects, CSPs are found throughout the whole insect development process from eggs and larvae to nymphal and adult stages [4, 16-19]. In locusts, they are mainly expressed in the antennae, tarsi and legs, and found to be associated with phase change [3-4, 20-22]. CSPs are not the apanage of insects. They are also expressed in many various organisms such as crustacean, shrimp and many other arthropod species [23]. However, they are not specific to the arthropod kingdom. They are also expressed at the level of the bacterial superkingdom, demonstrating their existence not only in eukaryotes, but also in prokaryote organisms [23-24]. Prokaryote CSPs are twins or identical twins to insect CSPs [24]. They have been reported from bacterial species such as coccobacillus Acinetobacter baumannii, Macrococcus/Staphylococcus caseolyticus, the filamentous actinomycete Kitasatospora griseola, an Actinobacteria genus in the family Streptomycetaceae, and Escherichia coli (E. coli) which are known as common bacteria from the digestive tract, main prokaryotic secondary metabolites, opportunistic multi-drug resistant pathogens, high positive cytochrome c oxidase reactions, and symbionts of multiple insect species [24]. Their existence has been mentioned in plants, but this still needs to be demonstrated experimentally [25-26]. CSPs can be extracted from wasp venom [27]. In moths, nearly all CSPs are expressed in the female pheromone gland [9-14].
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.